Skip to main content

Table 3 Summary of all adverse events by treatment group

From: A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled αvβ6 integrin inhibitor

 

Placebo

(N = 3)

GSK3008348 1000 mcg

(N = 5)

Number of participants with any AE, n (%)

1 (33)

3 (60)

Diarrhoea

1 (33)

0

Urinary tract infection

0

1 (20)

Headache

0

1 (20)

Contact dermatitis

0

1 (20)

Tooth extraction

0

1 (20)